Abstract | OBJECTIVE: METHOD: RESULTS: Two hundred twenty-eight patients were randomized ( atomoxetine n = 184, methylphenidate n = 44). Both drugs were associated with marked improvement in inattentive and hyperactive-impulsive symptom clusters as assessed by parents and investigators. No statistically significant differences between treatment groups were observed on the primary outcome measure (investigator-rated ADHD-IV Rating Scale total score: atomoxetine baseline: 39.4 [8.5], endpoint: 20.0 [13.9]; methylphenidate baseline: 37.6 [9.7], endpoint: 19.8 (16.6); p = .66). Safety and tolerability were also similar between the 2 drugs. Discontinuations due to adverse events were 10/184 (5.4%) for atomoxetine and 5/44 (11.4%) for methylphenidate; p = .175. CONCLUSION:
|
Authors | Christopher J Kratochvil, John H Heiligenstein, Ralf Dittmann, Thomas J Spencer, Joseph Biederman, Joachim Wernicke, Jeffrey H Newcorn, Charles Casat, Denai Milton, David Michelson |
Journal | Journal of the American Academy of Child and Adolescent Psychiatry
(J Am Acad Child Adolesc Psychiatry)
Vol. 41
Issue 7
Pg. 776-84
(Jul 2002)
ISSN: 0890-8567 [Print] United States |
PMID | 12108801
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidepressive Agents
- Central Nervous System Stimulants
- Propylamines
- Methylphenidate
- Atomoxetine Hydrochloride
|
Topics |
- Adolescent
- Antidepressive Agents
(therapeutic use)
- Atomoxetine Hydrochloride
- Attention Deficit Disorder with Hyperactivity
(drug therapy)
- Central Nervous System Stimulants
(therapeutic use)
- Child
- Female
- Humans
- Male
- Methylphenidate
(therapeutic use)
- Propylamines
(therapeutic use)
- Prospective Studies
|